Third, although our in vitro and in vivo findings support a functional role of MUC1 in tumor progression and drug sensitivity, additional mechanistic studies are warranted to explore whether MUC1 directly modulates the efficacy of tyrosine kinase inhibitors or simply marks a more responsive tumor subtype. The gene discussed is MUC1; the disease is neoplasm.